Actively Recruiting
Treatment for Aerobic Vaginitis Using Baofukang Vaginal Suppository Comparing 7-Day and 14-Day Regimens
Led by Peking University Shenzhen Hospital · Updated on 2025-06-12
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the treatment of aerobic vaginitis using Baofukang Suppository in two different durations. The study compares the effects of a 7-day treatment group versus a 14-day treatment group to assess both efficacy and safety. Participants are female and diagnosed with aerobic vaginitis based on specific clinical signs including vaginal discharge, elevated pH, and Donders score. Participants receive Baofukang Suppository vaginally at a dose of 1.74 grams, with two capsules administered each night. One group uses the suppository for 7 days, while the other group applies it for 14 days. Both groups are monitored after treatment at intervals of 7 to 14 days and again at 35 to 42 days to evaluate outcomes. During the study, participants will undergo assessments to determine the cure rate at one week and one month after treatment. Safety is also monitored by recording any side effects during the first week following treatment. The study involves random assignment to one of the two treatment groups, and participation includes follow-up visits for outcome evaluations. The total participant age range is from 18 to 55 years.
CONDITIONS
Brief Title
Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants aged 18 to 55 years
- Diagnosed with aerobic vaginitis based on vaginal discharge, pH greater than 4.5, and Donders score of 3 or higher
- Able to comply with study procedures and follow-up visits
You will not qualify if you...
- Having other types of vaginitis, cervical erosion, suspected gonorrhea, herpes simplex virus infection, or other vulvar diseases
- Received systemic or vaginal antifungal or antibiotic treatment within two weeks before enrollment
- Pregnant, breastfeeding, or planning pregnancy
- Women with liver or kidney dysfunction, low immune function, diabetes, psychosis, or other serious diseases
- Allergic to any ingredients in the study drug
- Poor compliance or inability to follow study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 7 to 14 days
Participants receive Baofukang Suppository vaginal suppositories either for 7 days or 14 days depending on their assigned group.
Daily self-administration for 7 or 14 days
Duration - Up to 6 weeks after treatment
Participants are evaluated for efficacy and safety 7 to 14 days and again 35 to 42 days after completing treatment.
2 visits (in-person)
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hosptal
Shenzhen, Guangdong, China, 518036
Actively Recruiting
Research Team
P
Ping Liu, M.D.
Y
Yiheng Liang, M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here